Servier India introduces ‘Ivosidenib’(Tibsovo®), in India, First-in-class Targeted Therapy in Oncology for Rare IDH1-Mutated AML and Cholangiocarcinoma
Marks an important development in oncology, providing a treatment option for patients with AML and cholangiocarcinoma in India. Announced during AML Awareness month, highlighting Servier...
